

A Hospital-based Study to Determine the Prevalence of Primary Isoniazid (INH) and Rifampicin Resistance among Individuals with Treatment-naïve Tuberculosis (TB) Cases

Girijesh Kumar

Associate Professor, Department of T.B and Chest , Nalanda Medical College and Hospital ,Patna, Bihar, India

Received: 17-04-2022 / Revised: 21-05-2022 / Accepted: 25-06-2022

Corresponding author: Dr. Girijesh Kumar

Conflict of interest: Nil

Abstract:

Aim: The present study was planned to find the prevalence of INH and Rifampicin resistance in the treatment naïve new tuberculosis cases. We also tried to find a correlation between sputum grading, sociodemographic factors, and resistance patterns.

Methods: It was a cross-sectional study done conducted for the period of six months. 200 patients were included in the study. Ethical clearance from the Institute Ethics Committee was obtained. All Adult patients attending Pulmonary medicine OPD who were diagnosed with new sputum smear-positive tuberculosis and have not received ATT drugs for more than 2 weeks were included in the study after taking informed written consent.

Results: A total of 200 newly diagnosed microbiologically confirmed cases of pulmonary tuberculosis were recruited in the study. Most of the patients were male (n=160, 80%) and a mean age of 45.435 (SD ±12.18) years. Based on the Modified Kuppuswamy socioeconomic scale 55% cases belonged to the lower socioeconomic group, whereas 35% belonged to the upper lower group. 20% were smokers and 80% were non-smokers. 85% patients presented with cough as chief complaint followed by Fever in 35%, loss of appetite in 50%, and loss of weight in 45% cases. Among comorbidities, Diabetes mellitus was most common followed by asthma. None of the cases had a previous history of anti-tubercular drug intake. All cases were HIV-Sero-negative.

Conclusion: INH resistance was found to be low (5.6%) with negligible MDR in the current study. Regular and large studies are needed to quantify and tackle the problem of primary MDR TB.

Keywords: Primary MDR TB, Tuberculosis, MGIT, Treatment naïve TB

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

According to the World Health Organisation (WHO) global report 2016, among 10.4 million incident TB cases worldwide, 3.9% are estimated to have had rifampicin- or multidrug-resistant tuberculosis (MDR/RR-TB) in 2015. In addition, 21% of previously treated TB cases were estimated to have had

MDR/RR-TB in the same year. MDR-TB is caused by strains of *M. tuberculosis* that is resistant to both isoniazid and rifampicin. Drug-resistant TB (DR-TB) patients require prolonged and expensive treatment using second-line medications that are less effective and more toxic.[1] The acquisition or emergence *M. tuberculosis* resistance

may occur from; previous exposures to quinolones[2], use of inferior regimens³, poor adherence to anti-TB drug, previous TB treatment[4,5], and high human immunodeficiency virus (HIV) co-infection.[6,7] The WHO recommends all presumptive TB patients to undergo DST although many countries still lack laboratory capacity to achieve this.[1] Therefore, in most low- and middle-income countries, there may be a high level of under-diagnosis and misdiagnosis of DR-TB. However, with the recent recommendation of rapid molecular diagnostic tests as a first-line TB screening test, there is progressive increase in reporting of DR-TB in resource-limited settings.[8,9]

The emergence of drug resistance to *M. tuberculosis* has become a significant obstacle for TB control.[10] The emergence and spreading of multidrug (MDR) and extensively (XDR) drug-resistant *M. tuberculosis* complex (MTBC) strains poses significant challenges to TB control.[11] Despite low sensitivity in detection of *M. tuberculosis*, acid-fast staining remains the main diagnostic method in resource-limited settings. Mycobacterial culture is the gold standard and the most sensitive method for TB diagnosis; however, its use in clinical practice is limited due to a slow turnaround time, biosafety requirements, and high cost.[12,13] In 2011, WHO introduced the wide use of Xpert MTB/RIF assay. It is a fully automated diagnostic molecular test using real-time polymerase chain reaction (PCR) technology to simultaneously detect *M. tuberculosis* and rifampicin resistance mutations in the *rpoB* gene.[14] One of the promising method, well evaluated and accepted in varying settings is the fluorimetry based liquid culture detection system, Mycobacterial Growth Indicator Tube (MGIT 960) (Becton and Dickinson, USA).[15]

With the above problem of primary drug resistance among newly diagnosed

tuberculosis cases the present study was planned to find the prevalence of INH and Rifampicin resistance in the treatment naïve new tuberculosis cases. We also tried to find a correlation between sputum grading, sociodemographic factors, and resistance patterns.

Materials and Methods

It was a cross-sectional study done conducted in Department of T.B and Chest , Nalanda Medical College and Hospital ,Patna, Bihar, India for the period of six months. 200 patients were included in the study. Ethical clearance from the Institute Ethics Committee was obtained. All Adult patients attending pulmonary Medicine OPD who were diagnosed with new sputum smear-positive tuberculosis and have not received ATT drugs for more than 2 weeks were included in the study after taking informed written consent.

Inclusion criteria

- Treatment naïve new tuberculosis cases (those cases who have received anti-tuberculosis drugs for less than 2 weeks)

Exclusion criteria

- Subjects who were previously treated for pulmonary or extrapulmonary tuberculosis for more than 2 weeks
- Subjects not willing to participate in the study

Suspected cases of tuberculosis were given a wide mouth bottle for collection of sputum. Two sputum specimens were collected (spot & early morning). Sputum was subjected to ZN and/or fluorescent stains (as per RNTCP/NTEP guidelines) and studied under light & Fluorescent microscopy respectively. Results were recorded and documented as per RNTCP guidelines. Patients with positive results were screened as per inclusion and exclusion criteria. Those patients with positive smears were asked to participate in the study and details of the study explained both verbal and documents. After taking

informed consent willing patients were asked to give 2 more samples in a sterile sputum collection bottle in Falcon tube for MGIT culture and DST.

Sputum samples were processed as per instructions by MGIT manufacturer FIND Diagnostics. The culture was done in MGIT 960 and positive cultures were recorded and subjected to drug sensitivity testing for INH (0.1 µg/ml) and Rifampicin (1 µg/ml) and a parallel nondrug MGIT was run as a control. Data were recorded and analysed.

Culture and drug susceptibility in liquid media (BACTEC MGIT 960)

The samples were processed as per the guideline For BACTECTM MGIT 960TM TB system given by the manufacturer FIND diagnostics.[16]

NaOH-NALC procedure

The equal volume of sputum sample and NaOH-NALC Sodium citrate solution was added and vortexed lightly around 15-30 seconds. NALC-NaOH solution was added to the mixture and allowed for 15-20 minutes (25 minutes max). Vortex was done lightly in every 5-10 minutes. Phosphate buffer (pH 6.8) was added up to the top ring and mixed well and centrifuged at 3000 rpm for 15-20 minutes and allowed the tubes to stand for 5 minutes to settle down. The supernatant was discarded carefully into the container containing a mycobactericidal disinfectant. Phosphate buffer (pH 6.8) 1-2 ml was added and resuspended the sediment with the help of a pipette or vortex mixer. Polymyxin B, Amphotericin B, Nalidixic acid, Trimethoprim, and Azlocillin (PANTA) was reconstituted according to the manufacturer's description and then used in MGIT tubes.

Inoculation into MGIT medium

7 ml MGIT tubes were aseptically added with 0.8 ml of MGIT growth supplement and PANTA and then 0.5 ml of a well-mixed processed/concentrated specimen

and mixed by inverting the tube several times. The tubes and caps were wiped with a Mycobactericidal disinfectant and inoculated tubes were kept at room temperature for 30 minutes. Inoculated MGIT (7 ml) tubes were then entered in the BACTEC MGIT 960 instruments after scanning. Tubes were incubated at 37°C. MGIT tubes were kept incubated until the instrument flagged them positive. Once a MGIT tube is flagged positive, the tubes were manually observed, and smear was made and stained with Auramine Rhodamine for AFB to rule out any contamination. After a maximum of 6 weeks, the instrument flags the tube negative if there is no growth. The second Sample was also subjected to the Line Probe Assay for cross-checking the resistance pattern, the sample was processed as per the manufacturer's guideline by Hain's MTBDR plus for LPA.[17,18]

Statistical analysis

Outcome variables: Resistance to INH and Rifampicin. Distribution of data on categorical variables related to gender, age, weight, sputum grade, sputum smear results, symptoms like cough, fever, haemoptysis, loss of appetite and loss of weight, presence and absence of HIV seropositivity, co-morbidities, smoking history, history of ATT, household contact and resistance to INH and Rifampicin etc. were expressed in frequency and percentage. The distribution of the variables was revealed via the Kolmogorov-Smirnov test. The correlation of Resistance and various variables like age, sex, symptoms, socioeconomic status (based on Modified Kuppusamy Scale 2019),[19] smoking, diabetes, and household contact history were analyzed by one-way Anova with Bonferroni correction using IBM-SPSS program (SPSS version 19.0; SPSS Inc, Chicago, IL) All statistical analysis was carried out at 5% level of significance and p-value <0.05 was considered as significant.

Results

Table 1: General characteristics of the cases

Characteristics	N%
Male	160 (80)
Female	40 (20)
Smokers	40 (20)
Non-Smoker	160 (80)
HIV Seropositive	0
Household Contact	10 (5)
Diabetes	30 (15)
Asthma	10 (5)
CKD	8 (4)
Hypertension	8 (4)
Previous history of ATT intake	0
Socioeconomic status(category)	
Lower(V)	110 (55)
Upper Lower (IV)	70 (35)
Lower Middle (III)	16 (8)
Upper Middle (II)	4 (2)
Upper (I)	0

A total of 200 newly diagnosed microbiologically confirmed cases of pulmonary tuberculosis were recruited in the study. Most of the patients were male (n=160, 80%) and a mean age of 45.435 (SD ±12.18) years. Based on the Modified

Kuppuswamy socioeconomic scale 55% cases belonged to the lower socioeconomic group, whereas 35% belonged to the upper lower group. 20% were smokers and 80% were non-smokers.

Table 2: Correlation of resistance with categorical variables

Categorical Variables	Result	INH Resistance n (%)		p value
		Absent n (%)	Present n (%)	
Gender	Male	150	10	0.545
	Female	40	0	
Rifampicin Resistance	Absent	180	20	0.055
	Present	0	0	
Cough	Absent	30	0	1.00
	Present	160	10	
Fever	Absent	65	5	1.000
	Present	120	10	
Haemoptysis	Absent	150	10	0.314
	Present	40	0	
Weight loss	Absent	100	10	0.634
	Present	80	10	
Loss of appetite	Absent	90	10	0.715
	Present	95	5	
Household Contact	Absent	90	7	1.000
	Present	10	0	
Jaundice	Absent	180	10	1.000

	Present	10	0	
Asthma	Absent	185	5	1.000
	Present	10	0	
DM	Absent	160	10	1.000
	Present	24	6	
Smoking	Absent	170	15	0.343
	Present	15	0	
Socioeconomic Status	Lower	105	5	0.625
	Upper Lower	65	5	
	Lower Middle	16	0	
	Upper Middle	4	0	

85% patients presented with cough as chief complaint followed by Fever in 35%, loss of appetite in 50%, and loss of weight in 45% cases. Among comorbidities, Diabetes mellitus was most common followed by asthma. None of the cases had a previous history of anti-tubercular drug intake. All cases were HIV-Sero-negative.

Discussion

The Global TB Report 2017 published by World Health Organization (WHO) estimates that India contributes 27% (2.79 million) and 25% (147 000) of the global burden of TB and multi-drug resistant TB (MDR-TB), respectively.[1,20] A male predominance of pulmonary tuberculosis with Male to Female ratio of 5.25:1 was noted in our study which probably reflects the study population distribution as a whole. Similar male gender predominance has also been noticed in other studies.[21,22] This gender difference may be due to the high prevalence of tuberculosis in the male population due to their exposure to external environment for their occupation and other related work.

Pressure to continue working in spite of poor health could lead to decreased compliance toward regular medication thereby increasing the threat of developing drug resistance. A national drug resistance survey found 58% males in the age group of 25-55 years and females more common in the younger age group (72% in 15-45 years).[23] In the present study the most common co-morbidity found as Diabetes,

followed by asthma, chronic kidney disease and hypertensive. Similar results have been found in previous studies also. In the study done by Myneedu et al most common comorbid condition found was diabetes (2%).[21]

A total of 200 newly diagnosed microbiologically confirmed cases of pulmonary tuberculosis were recruited in the study. Most of the patients were male (n=160, 80%) and a mean age of 45.435 (SD ±12.18) years. Based on the Modified Kuppuswamy socioeconomic scale 55% cases belonged to the lower socioeconomic group, whereas 35% belonged to the upper lower group. 20% were smokers and 80% were non-smokers. In the present study 20% cases were smokers, similar findings are also found in several studies. Harshita Gupta et al. in their study from Lucknow reported 64.4% smokers.[24] In a study done in New Delhi by Myneedu et al., found 49 out of 453 cases (10.8%) smokers.[21] Household contact to TB and MDR TB is a well-documented risk factor for developing Initial MDR TB.38 In our study, only four patients had household contact as tuberculosis. All were sensitive to both INH and Rifampicin. Gupta et al., in their study from Lucknow reported 23.3% of cases with a history of household contact of tuberculosis patients. They also found higher primary MDR and other combinations of drug resistance rates (4.7%).[24] All 200 (100%) samples showed growth of mycobacterium tuberculosis and on sensitivity 7 (7%)

showed resistance to INH, and none of the samples showed resistance to Rifampicin. This outcome is lower in contrast with national drug resistance survey of 2.2% of primary MDR.[21] In our study, mono-resistance to rifampicin was found to be zero; which is similar to the recently concluded first National Drug resistance survey (2014-16) of India.[23] 85% patients presented with cough as chief complaint followed by Fever in 35%, loss of appetite in 50%, and loss of weight in 45% cases. Among comorbidities, Diabetes mellitus was most common followed by asthma. None of the cases had a previous history of anti-tubercular drug intake. All cases were HIV-Sero-negative.

The limitation of the study was less number of cases. A large number of patients were from other states and did not give consent for the study due to logistic problems. Further none of our patients had HIV seropositivity which denied opportunity to study the impact of HIV on primary drug resistance. Similarly, very few patients had a history of household contact with tuberculosis patients and none of them had resistance, we could not study the impact of the same on primary drug resistance.

Conclusion

Primary drug resistance in treatment naïve cases of tuberculosis is not rare. Mono-resistance to Isoniazid is common (7%). Mono-resistance to Rifampicin is negligible. Primary MDR is also very less but present. The proper history of ATT exposure is of utmost importance to rule out primary drug resistance. Newer diagnostic techniques like CB-NAAT should be offered upfront to a newly diagnosed tuberculosis case to rule out primary drug resistance and proper treatment. A regular survey of drug resistance is very important for the knowledge of the problem and preparation for the same.

References

1. World Health Organisation. Global Tuberculosis Control: WHO report

2016. Geneva, Switzerland: World Health Organisation, 2016.

2. Deutschendorf C, Goldani LZ, Santos RP. Previous use of quinolones: a surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients?. *Brazilian Journal of Infectious Diseases*. 2012;16:142-5.
3. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. *European Respiratory Journal*. 2012 Jun 1;39(6):1511-9.
4. Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. *Journal of International Medical Research*. 2012 Apr;40(2):436-45.
5. Blöndal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. *Bulletin of the World Health Organization*. 2007;85:387-90.
6. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. *The Lancet*. 2004 Oct 2;364(9441):1244-51.
7. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. *PloS one*. 2009 May 15;4(5):e5561.
8. Duan Q, Chen Z, Chen C, Zhang Z, Lu Z, Yang Y, Zhang L. The prevalence of drug-resistant tuberculosis in mainland China: an updated systematic review and meta-analysis. *PLoS One*. 2016 Feb 9;11(2):e0148041.
9. Nasiri MJ, Dabiri H, Darban-Sarokhalil D, Rezadehbashi M, Zamani S. Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis. *American journal of infection control*. 2014 Nov 1;42(11):1212-8.

10. Multidrug WH. extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization. 2010;35(6):2171-8.
11. Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. *Journal of clinical microbiology*. 2011 Aug;49(8):3068-70.
12. Pinyopornpanish K, Chaiwarith R, Pantip C, Keawvichit R, Wongworapat K, Khamnoi P, Supparatpinyo K, Sirisanthana T. Comparison of Xpert MTB/RIF assay and the conventional sputum microscopy in detecting Mycobacterium tuberculosis in Northern Thailand. *Tuberculosis research and treatment*. 2015 Apr 30;2015.
13. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. Evaluation of the analytical performance of the Xpert MTB/RIF assay. *Journal of clinical microbiology*. 2010 Jul;48(7):2495-501.
14. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. *Journal of Infection*. 2012 Jun 1;64(6):580-8.
15. Garrigó M, Aragón LM, Alcaide F, Borrell S, Cardenosa E, Galán JJ, Gonzalez-Martín J, Martín-Casabona N, Moreno C, Salvado M, Coll P. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. *Journal of Clinical Microbiology*. 2007 Jun;45(6):1766-70.
16. Salman HS, Rüsç-Gerdes S. MGIT Procedure Manual. Mycobact Growth Indic Tube Cult Drug Susceptibility Demonstr Proj [Internet]; 2006.
17. Tagiliani E, C D. 2018.
18. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O'Brien R. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. *BMC infectious diseases*. 2010 Dec;10(1):1-7.
19. Saleem SM. Modified Kuppusswamy socioeconomic scale updated for the year 2019. *Indian J Forensic Community Med*. 2019;6(1):1-3.
20. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
21. Myneedu VP, Singhal R, Khayyam KU, Sharma PP, Bhalla M, Behera D, Sarin R. First and second line drug resistance among treatment naïve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi. *Journal of epidemiology and global health*. 2015 Dec 1;5(4):365-73.
22. Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. *Indian J Med Res*. 2004;120(4):377-86.
23. Ministry of Health and Family Welfare GoI. Report of the first national anti-tuberculosis drug resistance survey: India 2014-16;2018.
24. Gupta H, Kant S, Jain A, Natu SM, Ahluwalia S. Initial drug resistance pattern among pulmonary tuberculosis patients. *Indian J Tuberc*. 2013;60(3):154-61.